EGFR 突变 NSCLC 骨转移：奥希替尼时代的 SRE 与地舒单抗问题
类型: 回顾性研究 / 骨转移 发表日期: 2024-04 入库日期: 2026-05-21 来源: PubMed / JTO Clinical and Research Reports; Cancer Medicine 标签: EGFR L858R, 骨转移, 奥希替尼, 地舒单抗, SRE, 溶骨性病灶
Citations
Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib. JTO Clinical and Research Reports. 2023. PMID: 37168878. DOI: 10.1002/onco.13951
Assessing EGFR-mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy. Cancer Medicine. 2024. PMID: 38549499. DOI: 10.1002/cam4.7152
Why it matters for mom
Mom's initial PET-CT showed multiple bone metastases, and later imaging noted sternum/parasternal soft-tissue progression. These papers keep bone disease visible as its own management domain, not merely another tumor marker.
Practical takeaways
- Bone metastases remain clinically important even when EGFR-targeted therapy is active.
- SRE prevention, pain control, fracture risk, and local therapy should be tracked separately.
- Denosumab and radiation answer different questions and may both be needed.
Questions for doctors
- Is there any high-risk bone lesion that needs proactive radiation or orthopedic input?
- Should bone scan, MRI, or PET/CT be used to clarify activity in sternum/rib/spine lesions?
- Are current bone lesions lytic, sclerotic, mixed, or healing-response changes?